The BioProcess International Conference is your one-stop industry resource for driving down costs; improving quality; and achieving rapid, robust, and resilient process development and manufacturing. This is where challenges are explored, solutions are uncovered, and opportunities are developed — at the largest and most highly respected event solely dedicated to biopharmaceutical manufacturing.
New This Year-
New, unpublished data in every conference session
-
Reports from the FDA, EMA, and leading industry players on biosimilars and biobetters
-
Sessions on managing global manufacturing and development assets, facilities and partners
-
Viral clearance conference session
-
In-depth coverage of the development and production of antibody–drug conjugates
An expanded roster of preconference symposia will help you gain new skills and update your knowledge in a variety of areas:
Preconference Symposia, Monday, 31 October 2011: “Contamination Control — Lessons Learned, Best Practices, and Case Studies”; “Incorporating Single Use in Process Development and Scale-Up”;
“Understanding Lyophilization and Designing an Optimal Lyophilization Process”; “Global Strategies and Experience in the Development of Biosimilars”; “Case Studies of Process and Analytical Transfers in Biomanufacturing”; and “Using DoE Effectively for Process Characterization Without Getting Lost in the Statistics”
Training Courses, Tuesday and Wednesday 1–2 November 2011: “Introduction to Biopharmaceutical Manufacturing”; “Bioassay Method Development and Validation”; “Regulatory Requirements During Drug Development”; and “Introduction to Analytical Method Development and Validation for Therapeutic Proteins”
Tracks and Sessions-
Analytical Technologies for Biopharmaceutical Development
-
Biosimilars and Biobetters
-
Cell Culture and Upstream Processing
-
Enhancing Manufacturing and Development Efficiency and Flexibility
-
Formulation Strategies for Protein Therapeutics
-
Managing Global Manufacturing Facilities and Partners
-
Novel Approaches and Applications for Viral Clearance
-
Product Lifecycle Management
-
Recovery and Purification
-
Vaccine Development and Production
-
John G. Aunins (Merck Research Laboratories)
-
Jeffrey C. Baker (Consulting LSS Black Belt)
-
Michael Betenbaugh (Johns Hopkins University)
-
Timothy S. Charlebois (Pfizer)
-
Esa Heinonen (EMA Working Group on Biosimilars, Head of Section 2, Marketing Authorizations, Finnish Medicines Agency, Finland)
-
Steven Kozlowski (Office of Biotechnology Products, OPS, CDER, US FDA)
-
Tim Moore (Roche)
-
Robin A. Robinson (US Department of Health and Human Services)
-
Morris Rosenberg (Seattle Genetics)
-
Jay S. Stout (Merck & Co., Inc.)
IBC has designed three and four-day conferences package options to fit all your needs. Early registration is encouraged to take advantage of preregistration discounts. Discounts are also available to groups of three or more. Find complete details online, or call 1-800-309-4078. When registering, please mention this priority code: BPIFESEPT.
Attendees Say …“Always a great opportunity to get a very comprehensive overview of new trends in biologics process development, manufacturing aspects, and new trends in the biologics business.” — Wolfgang Noe (former VP of bioprocess development, Biogen Idec)
“A great opportunity for industrial networking.” — Joerg Von Hagen (R&D Manager, Merck)
“This conference is a great place to meet technical experts in the industry. I enjoyed exchanging research ideas with global companies and sparking new collaboration.” — Kelvin Lau (senior process engineer, Abbott)
“An excellent forum for sharing of lessons learned.” — Victor Awafo (deputy director of manufacturing technology, Sanofi Pasteur)